Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, August 7, 2024
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
[ Wed, Aug 07th 2024
] - WOPRAI
Tue, August 6, 2024
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
[ Tue, Aug 06th 2024
] - WOPRAI
Gena Wang Maintained (BCRX) at Hold with Increased Target to $7 on, Aug 6th, 2024
Gena Wang of Barclays, Maintained "BioCryst Pharmaceuticals, Inc." (BCRX) at Hold with Increased Target from $6 to $7 on, Aug 6th, 2024.
Gena has made no other calls on BCRX in the last 4 months.
There is 1 other peer that has a rating on BCRX. Out of the 1 peers that are also analyzing BCRX, 0 agree with Gena's Rating of Hold.
This is the rating of the analyst that currently disagrees with Gena
- Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $12 on, Tuesday, May 7th, 2024
